Zhongzhi Pharmaceutical (HKG:3737) expects a 90% year-over-year decline in net profit for the six months ended June 30, a Friday filing with the Hong Kong bourse said.
The drugmaker attributed the forecast to lower sales revenue due to a change in industry policies.